None of the companies have disclosed the price of the drug or their manufacturing capacities for the same. The duration of treatment of molnupiravir is much shorter compared to other therapies, which is a significant advantage as it reduces the pill burden and enhances compliance.įDA panel backs first-of-a-kind Covid-19 pill from Merck The recommended dose of the drug is 800 mg twice a day for five days. “Molnupiravir is an important addition to the portfolio of oral therapies available for treating Covid-19 patients,” said Kirti Ganorkar, CEO of India Business, Sun Pharma. The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan-India, the company informed in a regulatory filing on Tuesday.Īlso, Sun Pharmaceuticals informed that it will sell Molnupiravir in India under the brand name Molxvir. Cipla will soon make Cipmolnu® 200mg capsules available at all leading pharmacies and Covid treatment centres across the country. Covid-19: Hetero launches Movfor, Molnupiravir capsules to treat high-risk adult patientsĬipla Ltd, on the other hand, plans to launch Molnupiravir under the brand name Cipmolnu.
0 kommentar(er)
